Market cap
$4.2b
End-of-day close multiplied by current shares on issue.
EBO · NZX
EBOS Group is an NZX-listed healthcare / healthcare distribution company with HY24 - HY26 of published result briefings.
Snapshot
HY26, released 25 February 2026
| Metric | Value | Change |
|---|---|---|
| Revenue | $6.8b | ↑ +13.0% |
| EBITDA | $302.7m | ↑ +9.7% |
| NPAT | $124.8m | ↑ +12.9% |
| Operating cash flow | $46.6m | ↓ -75.5% |
| OCF / EBITDA % | 15.4% | ↓ -53.4pp |
| Net debt | $1.1b | ↑ +5.3% |
| Net debt / EBITDA | 3.7x | ↓ -4.1% |
| ROE % | 4.6% | ↑ +0.1pp |
| DPS | 57.0c | — Flat |
| Payout ratio vs NPAT % | 93.3% | ↓ -6.9pp |
Source: latest published briefing (HY26, released 25 February 2026). Change compares against the prior equivalent period: HY25, released 19 February 2025.
Valuation
A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.
The latest close and share count context for the market price.
Market cap
$4.2b
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
18.52x
Recent market cap compared with trailing earnings.
EPS
1.11
Recent filing-derived earnings per share.
PEG
1.44x
P/E compared with recent earnings growth.
EV/EBITDA
9.22x
Enterprise value compared with recent EBITDA.
P/FCF
34.54x
Market cap compared with recent free cash flow.
P/B
1.57x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
5.8%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Daily closes use the full available width, with hover and touch readouts against real observations. Expand opens the chart at reading size.
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Indexed lines compare direction from the first positive comparable filing point. The axis is an index, not dollars or cents.
Chat
Ask follow-up questions about EBOS Group's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Longitudinal view
The latest period is shown first.
| Metric | HY266 MONTHS25 February 2026 | FY2512 MONTHS27 August 2025 | HY256 MONTHS19 February 2025 | FY2412 MONTHS21 August 2024 | HY246 MONTHS21 February 2024 | Trend |
|---|---|---|---|---|---|---|
| Revenue | $6.8b | $12.3b | $6b | $13.2b | $6.6b | Chart |
| Revenue growth % | 13.0% | -7.0% | -9.0% | 7.8% | 7.1% | Chart |
| EBITDA | $302.7m | $555.6m | $275.8m | $605.6m | $303.1m | Chart |
| EBITDA margin % | 4.5% | 4.5% | 4.6% | 4.6% | 4.6% | Chart |
| PBT | $162.7m | $302.2m | $155.8m | $383.1m | $192m | Chart |
| PBT growth % | 4.4% | -21.1% | -18.9% | 2.6% | -0.3% | Chart |
| NPAT | $124.8m | $215.1m | $110.5m | $271.5m | $136.2m | Chart |
| NPAT growth % | 12.9% | -20.8% | -18.9% | 7.1% | 3.0% | Chart |
| Operating cash flow | $46.6m | $418.5m | $189.8m | $348.2m | $105.5m | Chart |
| OCF / EBITDA % | 15.4% | 75.3% | 68.8% | 57.5% | 34.8% | Chart |
| FCF pre-lease | -$24m | $273m | $126m | $229.8m | $39.1m | Chart |
| FCF post-lease | -$24m | $273m | $126m | $229.8m | $39.1m | Chart |
| DPS | 57.0c | 61.5c | 57.0c | 61.5c | 57.0c | Chart |
| Payout ratio vs NPAT % | 93.3% | 108.0% | 100.2% | 83.9% | 80.3% | Chart |
| Annual payout ratio vs EPS % | — | 108.0% | — | 83.9% | — | Chart |
| ROE % | 4.6% | 7.9% | 4.5% | 11.2% | 11.8% | Chart |
| Net debt | $1.1b | $918.3m | $1.1b | $1b | $1.1b | Chart |
| Net debt / EBITDA | 3.7x | 1.65x | 3.86x | 1.68x | 3.59x | Chart |
| Debtor days | 45 | 41 | 43 | 39 | 42 | Chart |
| Inventory days | 36 | 40 | 38 | 34 | 37 | Chart |
| Total assets | $7.6b | $7.3b | $6.8b | $6.7b | $6.9b | Chart |
Reference: annolyse.ai/companies/ebo
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Reported revenue across covered periods.
Like-period revenue growth where comparable.
Company-specific earnings measure where disclosed.
EBITDA-equivalent margin where revenue and earnings are source-backed.
Statutory profit after tax.
Cash generated from operations.
Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.
Cash conversion against earnings.
Operating cash flow less capex before leases.
Free cash flow after lease payments where available.
Return on equity.
Borrowings less cash; negative values indicate net cash.
Leverage ratio, suppressed where earnings are not meaningful.
Dividend per share declared for the period.
Dividend payout against statutory NPAT.
Receivables days where the working-capital inputs are source-backed.
Inventory days where the working-capital inputs are source-backed.
Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.
The setup & the reality
The latest result is checked against what the prior briefing said to watch.
Historical setup
From Reported PBT fell 21.1% while cash conversion rose to 75.3%
EBOS confirmed underlying EBITDA of $585m, inside the disclosed range of $575–600m. No forward targets were supplied in the extraction, so this briefing focuses on what the release does and does not support. The HY25 share of FY25 was 48.8% of revenue, 49.6% of EBITDA and 51.4% of NPAT, indicating broadly balanced halves with a marginally softer H2 NPAT.
The release does not provide quantified FY26 guidance. The gap between the 12.0% underlying revenue growth signal and the 15.1% underlying NPAT decline means the forward shape — particularly margin and finance-cost recovery — remains an open question.
Open questions
This briefing cannot assess whether the disclosed underlying growth is repeatable beyond FY25 or what the FY26 trading shape is expected to look like.
Archive
Every published Annolyse briefing for this company appears here in reverse chronological order.
HY26 · Released 25 February 2026
Revenue grew 13.0% and FY26 EBITDA guidance was reaffirmed, but operating cash flow fell to $46.6m and the dividend was not covered by free cash flow.
FY25 · Released 27 August 2025
Reported revenue and earnings fell sharply against a non-comparable prior period, but cash generation and leverage strengthened materially.
HY25 · Released 19 February 2025
Operating deleverage pushed the NPAT payout ratio to 100.2% while net debt to EBITDA crept up to 3.86x even as cash conversion rebounded.
FY24 · Released 21 August 2024
Cash conversion slid to 57.5% from 68.8% while the full-year dividend absorbed roughly 99.1% of free cash flow, tightening financial headroom.
HY24 · Released 21 February 2024
EBITDA rose 4.8% but operating cash fell 34.5% on a $140.3m inventory build, leaving the lifted 57.0c dividend uncovered by free cash flow.
Get the next EBOS Group result briefing and five-year history updates by email.